global glp-1 obesity drug market size forecast 2030 to Hit USD 66.57 Billion by 2035 GLP-1 Agonists Market Report 2025-2033,
Description
Overall, its important to examine risks and benefits for each person individually
Primary cardiovascular disease prevention is an important area of investigation
The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time
They share a common therapeutic value: improved glycaemic control, weight reduction, and protection against cardiovascular and renal outcomes
doi: 10.1016/j.tem.2020.02.006 [DOI] [PubMed] [Google Scholar] 133
